Fasting serum concentration of apolipoprotein B48 represents residual risks in patients with new-onset and chronic coronary artery disease-Reference-Cited by-同舟云学术

Fasting serum concentration of apolipoprotein B48 represents residual risks in patients with new-onset and chronic coronary artery disease

Published:2013-06 Issue: Volume:421 Page:51-56
ISSN:0009-8981
Container-title:Clinica Chimica Acta
language:en
Short-container-title:Clinica Chimica Acta

Author:

Mori Kenta,Ishida Tatsuro,Yasuda Tomoyuki,Monguchi Tomoko,Sasaki Maki,Kondo Kensuke,Hasokawa Minoru,Nakajima Hideto,Haraguchi Yoko,Sun Li,Shinohara Masakazu,Toh Ryuji,Nishimura Kunihiro,Hirata Ken-ichi

Funder

SENSHIN Medical Research Foundation

AstraZeneca

Ministry of Education, Culture, Sports, Science and Technology

Publisher

Elsevier BV

Subject

Biochemistry (medical),Clinical Biochemistry,Biochemistry,General Medicine

Reference23 articles.

1. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials;Mihaylova;Lancet,2012

2. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association;Miller;Circulation,2011

3. Triglycerides and remnant particles as risk factors for coronary artery disease;Nakamura;Curr Atheroscler Rep,2006

4. Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA;Sakai;J Lipid Res,2003

5. Fasting serum apolipoprotein B-48 can be a marker of postprandial hyperlipidemia;Masuda;J Atheroscler Thromb,2011

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effects of pemafibrate and omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study);Frontiers in Cardiovascular Medicine;2023-01-25

2. Physiological Bases for the Superiority of Apolipoprotein B Over Low‐Density Lipoprotein Cholesterol and Non–High‐Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk;Journal of the American Heart Association;2022-10-18

3. Hypertriglyceridemia, a causal risk factor for atherosclerosis, and its laboratory assessment;Clinical Chemistry and Laboratory Medicine (CCLM);2022-06-10

4. Postprandial Hyperlipidemia: Association with Inflammation and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis;Biomedicines;2022-01-08

5. Effects of Virgin Olive Oil and Phenol-Enriched Virgin Olive Oils on Lipoprotein Atherogenicity;Nutrients;2020-02-26